India , Pune – The Insight Partners has released a comprehensive report titled “Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share, Size, Trends, and Forecast by 2031. The cell and gene therapy contract development and manufacturing organization (CDMO) market is emerging as a cornerstone of innovation within the biopharmaceutical industry. As personalized medicine gains momentum, the demand for expert, specialized contract manufacturing solutions is surging to accommodate the complex production of cell and gene therapies.

Biotech startups and established pharmaceutical companies alike face significant challenges in manufacturing these advanced therapies, which require highly technical and regulated environments. CDMOs offer essential services across development, scale-up, regulatory compliance, and production, enabling companies to accelerate clinical development timelines and bring transformative therapies to patients more efficiently.

Market Size, Share, Trends, Analysis, and Forecast (By 2031)

• The global market is expanding rapidly, driven by ongoing gene and cell therapy clinical trials and increased commercialization efforts.
• The cell and gene therapy contract development and manufacturing organization market size is projected to reach US$ 31.86 billion by 2031 from US$ 6.22 billion in 2024. The market is expected to register a CAGR of 26.4% during 2025–2031. The rising integration of AI and digital transformation is likely to bring in new market trends during the forecast period.
• North America leads, supported by a well-established biotech ecosystem, regulatory support, and pioneering research institutions.
• Europe holds significant market share, propelled by stringent quality standards and growing industry collaborations.
• Asia Pacific is the fastest-growing region, fueled by expanding biopharma investments, increasing clinical trials, and favorable regulatory reforms.
• The rise in rare disease treatments, oncology therapies, and CAR-T therapies is expanding market demand.
• Contract manufacturing services are critical for developers lacking in-house capabilities to meet complex production requirements.
• Technological integration, including AI and automation in manufacturing processes, is shaping efficiency and scalability.

Global and Regional Market Analysis

North America retains dominant market leadership by virtue of its advanced healthcare infrastructure, high R&D spending, and strong regulatory frameworks facilitating innovation. The U.S. is a major hub for CDMO activity, supported by collaborations between pharma and contract manufacturers.

Europe’s mature market benefits from regulatory harmonization across countries and widespread adoption of advanced therapies. Germany, France, and the UK stand out as centers of innovation and manufacturing capacity.

Asia Pacific’s rapid growth is supported by rising biotech ecosystems in China, Japan, South Korea, and India. Investments from local governments and private enterprises are fueling infrastructure development and clinical trial activities, positioning the region as a key contributor.

Emerging markets in Latin America, the Middle East, and Africa show increasing interest as healthcare infrastructure improves and awareness of advanced therapies rises.

Key Drivers Accelerating Market Growth

• The rising number of cell and gene therapy clinical trials targeting cancer, rare diseases, and genetic disorders.
• Growing outsourcing trend as companies seek specialized expertise, cost efficiency, and scalable manufacturing.
• Technological advancements such as AI and automation improving production efficiencies and quality control.
• Increasing regulatory clarity and support encouraging adoption of advanced biologics.
• Expansion of contract manufacturing capabilities to serve diverse therapy types including CAR-T and viral vector production.
• Collaboration between industry stakeholders driving innovation and reducing time-to-market.

Get sample PDF of the report -https://www.theinsightpartners.com/sample/TIPRE00040769

Key Players Leading Market Innovation

• WuXi Biologics Inc
• Charles River Laboratories International Inc
• Catalent Inc
• Lonza Group AG
• Thermo Fisher Scientific Inc.
• AGC Biologics AS
• Takara Bio Inc
• FUJIFILM Holdings Corp
• Pluri Inc, SK pharmteco Inc
• Aenova Holding GmbH

Emerging Trends and Market Opportunities

• The growth of CAR-T and gene-modified cell therapies requiring specialized, scalable manufacturing solutions.
• Increasing adoption of single-use bioreactors and continuous processing to enhance process efficiency.
• Expansion of decentralized manufacturing models to support global clinical trial supply chains.
• Integration of AI for predictive analytics, quality monitoring, and process optimization.
• Growing focus on sustainable manufacturing practices to minimize environmental impact.
• New partnership models between biotech innovators and CDMOs to accelerate personalized medicine delivery.

Recent Industry Developments

• Strategic partnerships, such as the collaboration between Autologous Therapeutics and AGC Biologics, accelerating CAR-T therapy development.
• Launch of innovative manufacturing platforms like Lakhesys Benchtop Cell Factory aimed at enhancing CAR-T production efficiency.
• Investment in automation and digital transformation by leading CDMOs to increase throughput and reliability.
• Regulatory authorities enhancing guidance on advanced therapy medicinal products (ATMPs), streamlining approval processes.
• Expansion of manufacturing facilities across key regions including North America, Europe, and Asia Pacific to address growing pipeline demands.

Conclusion

The cell and gene therapy CDMO market represents a rapidly growing segment essential for transforming the future of medicine. With an expanding pipeline of innovative therapies, increasing clinical trial activities, and greater focus on personalized care, CDMOs are key enablers in bridging complex manufacturing challenges and timely patient access. Regional growth dynamics, technological breakthroughs, and collaborative ecosystems are shaping a promising future, poised for remarkable expansion and impact through 2031.

Trending Related Reports

• Fluorine-18 Market – Global Forecast by 2030
• High Potent Pharmaceuticals Product Market – Growth Analysis through 2030
• Prescription Drugs Market – Outlook by 2030
• Biopharmaceutical Contract Manufacturing Market  – Global Trends by 2030

About The Insight Partners

The Insight Partners is a global leader in market research, delivering comprehensive analysis and actionable insights across diverse industries. The company empowers decision-makers with data-driven intelligence to navigate evolving markets and accelerate growth.

Contact Us:

• Contact Person: Ankit Mathur
• E-mail: [email protected]

Phone: +1-646-491-9876

Also Available in :

 Korean | German  | Japanese  | French  | Chinese  | Italian | Spanish

Frequently Asked Questions

Q: What are Cell and Gene Therapy CDMOs?
A: They are specialized contract organizations providing development, manufacturing, and regulatory services for cell and gene therapies, helping biotech and pharma companies bring these advanced treatments to market.

Q: What factors are driving growth in this market?
A: Key drivers include increased clinical trials, rising outsourcing, technological advances, regulatory support, and demand for therapies targeting cancer and rare diseases.

Q: Which regions dominate the market?
A: North America leads, followed by Europe, with Asia Pacific growing rapidly due to investment and infrastructure development.

Q: What are key emerging trends?
A: Trends include increased use of automation, expansion of CAR-T therapies, decentralized manufacturing, AI integration, and sustainable production practices.